These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 30049371)

  • 1. Erratum to: Kerr KM. The PD-L1 immunohistochemistry biomarker: two steps forward, one step back? J Thorac Oncol. 2018;13(3):291-294.
    J Thorac Oncol; 2018 Aug; 13(8):1230. PubMed ID: 30049371
    [No Abstract]   [Full Text] [Related]  

  • 2. Erratum to: Kiesgen S, Chicaybam L, Chintala N.K, Adusumilli P.S. Chimeric antigen receptor (CAR) t-cell therapy for thoracic malignancies. J Thorac Oncol. 2018;13(1):16-26.
    J Thorac Oncol; 2018 Aug; 13(8):1229. PubMed ID: 30049370
    [No Abstract]   [Full Text] [Related]  

  • 3. Erratum to: Derks JL, Leblay N, Lantuejoul S, Dingemans A-M, Speel, E-JM, Fernandez-Cuesta L. New insights into the molecular characteristics of pulmonary carcinoids and large cell neuroendocrine carcinomas, and the impact on their clinical management. J Thorac Oncol. 2018;13(6):752-766.
    J Thorac Oncol; 2018 Aug; 13(8):1229. PubMed ID: 30049369
    [No Abstract]   [Full Text] [Related]  

  • 4. Erratum to: Pyo KH, Lim SM, Kim HR, Sung YH, Yun MR, Kim S-M, et al. Establishment of a Conditional Transgenic Mouse Model Recapitulating EML4-ALK-Postive Human Non-Small Cell Lung Cancer. J Thorac Oncol. 2017;12(3):491-500.
    J Thorac Oncol; 2017 Dec; 12(12):1859. PubMed ID: 29169522
    [No Abstract]   [Full Text] [Related]  

  • 5. Programmed death ligand-1 expression is associated with poor disease free survival in salivary gland carcinomas.
    Mukaigawa T; Hayashi R; Hashimoto K; Ugumori T; Hato N; Fujii S
    J Surg Oncol; 2016 Jul; 114(1):36-43. PubMed ID: 27111278
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PD-L1 Expression in Lung Cancer.
    Yu H; Boyle TA; Zhou C; Rimm DL; Hirsch FR
    J Thorac Oncol; 2016 Jul; 11(7):964-75. PubMed ID: 27117833
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of the PD-L1 status by immunohistochemistry: challenges and perspectives for therapeutic strategies in lung cancer patients.
    Ilie M; Hofman V; Dietel M; Soria JC; Hofman P
    Virchows Arch; 2016 May; 468(5):511-25. PubMed ID: 26915032
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Checkpoint inhibitors: the new treatment paradigm for urothelial bladder cancer.
    Katz H; Wassie E; Alsharedi M
    Med Oncol; 2017 Sep; 34(10):170. PubMed ID: 28864844
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Non-Small Cell Lung Cancer, PD-L1, and the Pathologist.
    Kerr KM; Nicolson MC
    Arch Pathol Lab Med; 2016 Mar; 140(3):249-54. PubMed ID: 26927720
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PD-L1 immunohistochemistry for non-small cell lung carcinoma: which strategy should be adopted?
    Hofman P
    Expert Rev Mol Diagn; 2017 Dec; 17(12):1097-1108. PubMed ID: 29069958
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Validated programmed cell death ligand 1 immunohistochemistry assays (E1L3N and SP142) reveal similar immune cell staining patterns in melanoma when using the same sensitive detection system.
    Schats KA; Van Vré EA; De Schepper S; Boeckx C; Schrijvers DM; Waelput W; Fransen E; Vanden Bempt I; Neyns B; De Meester I; Kockx MM
    Histopathology; 2017 Jan; 70(2):253-263. PubMed ID: 27496355
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Letter to the Editor Regarding "Long-Term Follow-Up of Ground-Glass Nodules After 5 Years of Stability." by Lee et al., J Thorac Oncol 2019;14:1370-7.
    Huang CY; Huang CC; Huang WM; Liang CH; Wu FZ
    Heart Lung Circ; 2020 Sep; 29(9):e254-e257. PubMed ID: 32224087
    [No Abstract]   [Full Text] [Related]  

  • 13. PD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysis.
    Passiglia F; Bronte G; Bazan V; Natoli C; Rizzo S; Galvano A; Listì A; Cicero G; Rolfo C; Santini D; Russo A
    Oncotarget; 2016 Apr; 7(15):19738-47. PubMed ID: 26918451
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cellular Expression of PD-L1 in the Peripheral Blood of Lung Cancer Patients is Associated with Worse Survival.
    Boffa DJ; Graf RP; Salazar MC; Hoag J; Lu D; Krupa R; Louw J; Dugan L; Wang Y; Landers M; Suraneni M; Greene SB; Magaña M; Makani S; Bazhenova L; Dittamore RV; Nieva J
    Cancer Epidemiol Biomarkers Prev; 2017 Jul; 26(7):1139-1145. PubMed ID: 28446544
    [No Abstract]   [Full Text] [Related]  

  • 15. [Predictive PD-L1 immunohistochemistry for non-small cell lung cancer : Current state of the art and experiences of the first German harmonization study].
    Scheel AH; Dietel M; Heukamp LC; Jöhrens K; Kirchner T; Reu S; Rüschoff J; Schildhaus HU; Schirmacher P; Tiemann M; Warth A; Weichert W; Fischer RN; Wolf J; Büttner R
    Pathologe; 2016 Nov; 37(6):557-567. PubMed ID: 27510417
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PD-L1 promoter methylation is a prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients following radical prostatectomy.
    Gevensleben H; Holmes EE; Goltz D; Dietrich J; Sailer V; Ellinger J; Dietrich D; Kristiansen G
    Oncotarget; 2016 Nov; 7(48):79943-79955. PubMed ID: 27835597
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PD-L1: a novel prognostic biomarker in head and neck squamous cell carcinoma.
    Müller T; Braun M; Dietrich D; Aktekin S; Höft S; Kristiansen G; Göke F; Schröck A; Brägelmann J; Held SAE; Bootz F; Brossart P
    Oncotarget; 2017 Aug; 8(32):52889-52900. PubMed ID: 28881780
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Investigation of PD-L1 Biomarker Testing Methods for PD-1 Axis Inhibition in Non-squamous Non-small Cell Lung Cancer.
    Sheffield BS; Fulton R; Kalloger SE; Milne K; Geller G; Jones M; Jacquemont C; Zachara S; Zhao E; Pleasance E; Laskin J; Jones SJ; Marra MA; Yip S; Nelson BH; Gown AM; Ho C; Ionescu DN
    J Histochem Cytochem; 2016 Oct; 64(10):587-600. PubMed ID: 27591097
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [PD-L1 expression: An emerging biomarker in non-small cell lung cancer].
    Adam J; Planchard D; Marabelle A; Soria JC; Scoazec JY; Lantuéjoul S
    Ann Pathol; 2016 Jan; 36(1):94-102. PubMed ID: 26778219
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Programmed Death - Ligand 1 Expression Distinguishes Invasive Encapsulated Follicular Variant of Papillary Thyroid Carcinoma from Noninvasive Follicular Thyroid Neoplasm with Papillary-like Nuclear Features.
    Fu G; Polyakova O; MacMillan C; Ralhan R; Walfish PG
    EBioMedicine; 2017 Apr; 18():50-55. PubMed ID: 28363612
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.